This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Apyx Medical (APYX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -5.56% and 4.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ayr Wellness Inc. (AYRWF) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of -30.77% and 1.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.96% and 8.66%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -22.22% and 6.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -46.15% and 1.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor (OMI) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 1.47% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Biote Corp. (BTMD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
biote Corp. (BTMD) delivered earnings and revenue surprises of -237.50% and 4.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Apyx Medical (APYX) This Year?
by Zacks Equity Research
Here is how Apyx Medical (APYX) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
Apyx Medical (APYX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 8.33% and 4.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 16.67% and 0.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why You Should Add Humana (HUM) Stock to Your Portfolio Now
by Zacks Equity Research
Humana's (HUM) strength in Individual Medicare Advantage business and state-based contract wins are likely to be major tailwinds.
Here's Why Buying Brookdale (BKD) Stock is a Prudent Move Now
by Zacks Equity Research
For the second quarter, Brookdale (BKD) expects RevPAR growth to be in the range of 11.5-12%.
Here's Why Hold Strategy is Apt for The Joint (JYNT) Stock Now
by Zacks Equity Research
The Joint (JYNT) is expected to keep growing due to rising patient visits and new clinic openings.
The Joint (JYNT) Buys Wisconsin Regional Developer Zone Rights
by Zacks Equity Research
The Joint (JYNT) expects the Wisconsin region to hold a total of 53 clinics, of which 21 are currently operating.
Is Abcam (ABCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Abcam PLC Sponsored ADR (ABCM) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Humana (HUM) Sees Insurance Costs at Upper Limit of Guidance
by Zacks Equity Research
Despite the rising demand for elective procedures, Humana (HUM) sticks to its earnings guidance.
Is Apyx Medical (APYX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Apyx Medical (APYX) and Haemonetics (HAE) have performed compared to their sector so far this year.
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -60% and 12.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZimVie Inc. (ZIMV) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ZimVie Inc. (ZIMV) delivered earnings and revenue surprises of 525% and 9.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Apyx Medical (APYX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -41.67% and 24.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -30.77% and 7.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Quidel (QDEL) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 25.65% and 21.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LeMaitre Vascular (LMAT) Q1 Earnings Miss Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of -3.57% and 1.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) to Join S&P 500 Driven by Medicare Performance
by Zacks Equity Research
Molina Healthcare (MOH) is likely to leave S&P MidCap 400 and replace IHS Markit Ltd. in the S&P 500 Index.
Medtronic (MDT) Undertakes Investment to Advance STEM Education
by Zacks Equity Research
The Medtronic Foundation, solely funded by Medtronic plc (MDT), entered into 13 new partnerships to bridge the inequity in STEM education among underrepresented and underserved communities.